Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients with acute anterior wall myocardial infarction.

[1]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[2]  R. Magorien,et al.  Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction. , 1992, The American journal of cardiology.

[3]  J. Wójcik,et al.  Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. , 1992, Journal of the American College of Cardiology.

[4]  U. Tebbe,et al.  Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS) , 1992, Journal of the American College of Cardiology.

[5]  K. Swedberg,et al.  Dynamic QRS complex and ST segment vectorcardiographic monitoring can identify vessel patency in patients with acute myocardial infarction treated with reperfusion therapy. , 1991, American heart journal.

[6]  S. Hohnloser,et al.  Assessment of coronary artery patency after thrombolytic therapy: accurate prediction utilizing the combined analysis of three noninvasive markers. , 1991, Journal of the American College of Cardiology.

[7]  J. Mehta,et al.  Concurrent nitroglycerin administration decreases thrombolytic potential of tissue-type plasminogen activator. , 1991, Journal of the American College of Cardiology.

[8]  J. Mehta,et al.  Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis. , 1990, Circulation.

[9]  U. Tebbe,et al.  Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.

[10]  J. Stamler,et al.  Synergistic Disaggregation of Platelets by Tissue-Type Plasminogen Activator, Prostaglandin El9 and Nitroglycerin , 1989, Circulation research.

[11]  B. Sobel,et al.  Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration. , 1989, Circulation.

[12]  H. Gold,et al.  Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator. , 1988, Circulation.

[13]  B. Sobel,et al.  Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. , 1988, Circulation.

[14]  S. Forman,et al.  Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. , 1987, Journal of the American College of Cardiology.

[15]  R. W. Brower,et al.  Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. , 1987, The American journal of cardiology.

[16]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[17]  M. Krucoff,et al.  Noninvasive detection of coronary artery patency using continuous ST-segment monitoring. , 1986, The American journal of cardiology.

[18]  E. Kruithof,et al.  Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. , 1984, Blood.

[19]  P. Rentrop,et al.  Patterns of creatine kinase release during acute myocardial infarction after nonsurgical reperfusion: comparison with conventional treatment and correlation with infarct size. , 1984, Journal of the American College of Cardiology.

[20]  R. Ideker,et al.  Evaluation of a QRS scoring system for estimating myocardial infarct size. III. Correlation with quantitative anatomic findings for inferior infarcts. , 1984, The American journal of cardiology.

[21]  J. Mehta,et al.  Comparative Effects of Nitroprusside and Nitroglycerin on Platelet Aggregation in Patients with Heart Failure , 1980, Journal of cardiovascular pharmacology.